Case Page

 

Case Status:    DISMISSED    
On or around 01/23/2015 (Other)

Filing Date: January 15, 2014

According to the law firm press release, Gentium is a biopharmaceutical company focused on the development and manufacturing of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments.

On December 19, 2013, Gentium and Jazz jointly announced that they had entered into a tender offer agreement by which Jazz will acquire the Company for $57.00 per share in cash in a tender offer that will expire on January 22, 2014. The complaint alleges that, in an attempt to secure shareholder support for the unfair Proposed Acquisition, on December 24, 2013, Gentium filed with the SEC a materially false and misleading Schedule 14D 9 Solicitation/Recommendation Statement (the “14D 9”), which was also disseminated to Gentium’s shareholders. The 14D 9, which recommends that Gentium’s shareholders tender their shares to Jazz, omits and/or misrepresents material information in contravention of §§14(e) and 20(a) of the 1934 Act regarding the unfair consideration offered in the Proposed Acquisition, and the actual intrinsic value of the Company.

On May 9, 2014, the Court appointed Lead Plaintiff and approved their selection of Lead Counsel. On September 2, 2014, the Lead Plaintiff filed an amended complaint.

On January 22, 2015, the Court issued an Order granting Defendant's Motion to dismiss. The Clerk was directed to close this case.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Italy

SECURITIES INFORMATION:

Ticker Symbol: GENT
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 14-CV-00287
JUDGE: Hon. Oetken
DATE FILED: 01/15/2014
CLASS PERIOD START: 12/19/2013
CLASS PERIOD END: 01/15/2014
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Powers Taylor LLP

    ·
  2. Robbins Geller Rudman & Dowd LLP (Melville)
    58 South Service Road, Suite 200, Robbins Geller Rudman & Dowd LLP (Melville), NY 11747
    631.367.7100 631.367.1173 ·
  3. The Briscoe Law Firm, PLLC
    The Preston Commons, 8117 Preston Road, Suite 300, The Briscoe Law Firm, PLLC, TX 75255
    214.706.9314 214.706.9315 ·
No Document Title Filing Date
COURT: S.D. New York
DOCKET #: 14-CV-00287
JUDGE: Hon. Oetken
DATE FILED: 09/02/2014
CLASS PERIOD START: 12/19/2013
CLASS PERIOD END: 01/15/2014
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Faruqi & Faruqi LLP (New York)
    685 3rd Avenue 26th Floor, Faruqi & Faruqi LLP (New York), NY
    212..983.9330 212..983.9331 ·
No Document Title Filing Date